Essex Bio-technology Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
1,450
- Stock Symbol
-
01061
- Investments
-
7
- Share Price
-
$0.56
- (As of Monday Closing)
Essex Bio-technology General Information
Description
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Contact Information
Website
www.essexbio.comCorporate Office
- Room 2818, China Merchants Tower
- Shun Tak Centre, 168-200 Connaught Road Central
- Hong Kong
- Hong Kong
Corporate Office
- Room 2818, China Merchants Tower
- Shun Tak Centre, 168-200 Connaught Road Central
- Hong Kong
- Hong Kong
Essex Bio-technology Stock Performance
As of 19-May-2025, Essex Bio-technology’s stock price is $0.56. Its current market cap is $317M with 567M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.56 | $0.56 | $0.28 - $0.66 | $317M | 567M | 1.65M | $0.07 |
Essex Bio-technology Financials Summary
As of 31-Dec-2024, Essex Bio-technology has a trailing 12-month revenue of $214M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 179,759 | 179,759 | 172,735 | 291,594 |
| Revenue | 213,990 | 213,990 | 221,858 | 168,269 |
| EBITDA | 54,594 | 54,594 | 51,699 | 38,929 |
| Net Income | 39,371 | 39,371 | 35,158 | 28,785 |
| Total Assets | 384,240 | 384,240 | 361,844 | 347,142 |
| Total Debt | 24,092 | 24,092 | 37,626 | 62,678 |
Essex Bio-technology Comparisons
Industry
Financing
Details
Essex Bio-technology Competitors (4)
One of Essex Bio-technology’s 4 competitors is GlaxoSmithKline Consumer Nigeria, a Corporation company based in Lagos, Nigeria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria | ||||
| Pfizer Manufacturing Austria | Corporation | Orth An Der Donau, Austria | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Taibang Biological Group | Private Equity-Backed | Beijing, China |
Essex Bio-technology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Essex Bio-technology Investments & Acquisitions (7)
Essex Bio-technology’s most recent deal was a Early Stage VC with CytoMed Therapeutics for . The deal was made on 18-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CytoMed Therapeutics | 18-Oct-2022 | Early Stage VC | Medical Supplies | ||
| Mito.Tech | 30-Aug-2019 | Later Stage VC | Drug Discovery | ||
| Wuhan Yadian Biotechnology | 01-Apr-2019 | Merger/Acquisition | Other Devices and Supplies | ||
| DB Therapeutics | 30-Oct-2018 | Early Stage VC | Medical Supplies | ||
| Mito.Tech | 28-Aug-2018 | Later Stage VC | Drug Discovery |
Essex Bio-technology ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
31.72 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Essex Bio-technology Exits (2)
Essex Bio-technology’s most recent exit was on 09-May-2016 from AC Immune. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| AC Immune | 09-May-2016 | Completed |
|
||
| Abpro | 06-Apr-2016 | Later Stage VC | Completed |
Essex Bio-technology Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Wuhan Yadian Biotechnology | Wuhan, China |
Essex Bio-technology FAQs
-
When was Essex Bio-technology founded?
Essex Bio-technology was founded in 2000.
-
Where is Essex Bio-technology headquartered?
Essex Bio-technology is headquartered in Hong Kong, Hong Kong.
-
What is the size of Essex Bio-technology?
Essex Bio-technology has 1,450 total employees.
-
What industry is Essex Bio-technology in?
Essex Bio-technology’s primary industry is Pharmaceuticals.
-
Is Essex Bio-technology a private or public company?
Essex Bio-technology is a Public company.
-
What is Essex Bio-technology’s stock symbol?
The ticker symbol for Essex Bio-technology is 01061.
-
What is the current stock price of Essex Bio-technology?
As of 19-May-2025 the stock price of Essex Bio-technology is $0.56.
-
What is the current market cap of Essex Bio-technology?
The current market capitalization of Essex Bio-technology is $317M.
-
What is Essex Bio-technology’s current revenue?
The trailing twelve month revenue for Essex Bio-technology is $214M.
-
Who are Essex Bio-technology’s competitors?
GlaxoSmithKline Consumer Nigeria, Pfizer Manufacturing Austria, Pfizer Pakistan, and Taibang Biological Group are competitors of Essex Bio-technology.
-
What is Essex Bio-technology’s annual earnings per share (EPS)?
Essex Bio-technology’s EPS for 12 months was $0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
